About Protocadherin-17
Protocadherin-17 (PCDH17) is a protein
from Homo sapiens identified by UniProt accession
O14917, 1159 residues long.
MolForge cross-references it against 0 known binders and
105 disease associations.
Target properties
| Protein name | Protocadherin-17 |
|---|
| UniProt accession | O14917 |
|---|
| Gene | PCDH17 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 1159 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (105)
Diseases linked to this target (Open Targets).
- self reported educational attainment · score 0.51
- body mass index · score 0.47
- body fat percentage · score 0.46
- intelligence · score 0.45
- diet measurement · score 0.42
- schizophrenia · score 0.41
- cognitive function measurement · score 0.38
- mathematical ability · score 0.38
- type 2 diabetes mellitus · score 0.37
- C-reactive protein measurement · score 0.36
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-O14917-F1 | alphafold | PREDICTED | 67.70 | — |
Amino-acid sequence (1159 residues)
MYLSICCCFL LWAPALTLKN LNYSVPEEQG AGTVIGNIGR DARLQPGLPP AERGGGGRSK SGSYRVLENS APHLLDVDAD SGLLYTKQRI DRESLCRHNA KCQLSLEVFA NDKEICMIKV EIQDINDNAP SFSSDQIEMD ISENAAPGTR FPLTSAHDPD AGENGLRTYL LTRDDHGLFG LDVKSRGDGT KFPELVIQKA LDREQQNHHT LVLTALDGGE PPRSATVQIN VKVIDSNDNS PVFEAPSYLV ELPENAPLGT VVIDLNATDA DEGPNGEVLY SFSSYVPDRV RELFSIDPKT GLIRVKGNLD YEENGMLEID VQARDLGPNP IPAHCKVTVK LIDRNDNAPS IGFVSVRQGA LSEAAPPGTV IALVRVTDRD SGKNGQLQCR VLGGGGTGGG GGLGGPGGSV PFKLEENYDN FYTVVTDRPL DRETQDEYNV TIVARDGGSP PLNSTKSFAI KILDENDNPP RFTKGLYVLQ VHENNIPGEY LGSVLAQDPD LGQNGTVSYS ILPSHIGDVS IYTYVSVNPT NGAIYALRSF NFEQTKAFEF KVLAKDSGAP AHLESNATVR VTVLDVNDNA PVIVLPTLQN DTAELQVPRN AGLGYLVSTV RALDSDFGES GRLTYEIVDG NDDHLFEIDP SSGEIRTLHP FWEDVTPVVE LVVKVTDHGK PTLSAVAKLI IRSVSGSLPE GVPRVNGEQH HWDMSLPLIV TLSTISIILL AAMITIAVKC KRENKEIRTY NCRIAEYSHP QLGGGKGKKK KINKNDIMLV QSEVEERNAM NVMNVVSSPS LATSPMYFDY QTRLPLSSPR SEVMYLKPAS NNLTVPQGHA GCHTSFTGQG TNASETPATR MSIIQTDNFP AEPNYMGSRQ QFVQSSSTFK DPERASLRDS GHGDSDQADS DQDTNKGSCC DMSVREALKM KTTSTKSQPL EQEPEECVNC TDECRVLGHS DRCWMPQFPA ANQAENADYR TNLFVPTVEA NVETETYETV NPTGKKTFCT FGKDKREHTI LIANVKPYLK AKRALSPLLQ EVPSASSSPT KACIEPCTST KGSLDGCEAK PGALAEASSQ YLPTDSQYLS PSKQPRDPPF MASDQMARVF ADVHSRASRD SSEMGAVLEQ LDHPNRDLGR ESVDAEEVVR EIDKLLQDCR GNDPVAVRK
Explore Protocadherin-17 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets